Tayside Flow Technologies raises $1.82 Million
Printer Print Email Email
London: Tayside Flow Technologies has raised $1.82 million in a funding round which involves investors Quayle Munro Holdings, Sir Tom Farmer, Braveheart Investment Group and Scottish Enterprise. The company management and private investors also participated in the round. TFT received its first VC funding in 2001 as a spin out from Tayside University Hospitals NHS Trust. The Company specializes in technology that reintroduces the human body's natural blood flow pattern, known as Spiral Laminar Flow (SLF), a technology that will be used in medical implants. By reintroducing natural blood flow, SLF can reduce blood flow turbulence and disturbance in implants such as grafts and stents, thereby increasing patency and mitigating downstream disease progression. TFT has made significant progress in the past 12 months and will use the additional funding to further register and commercialize its novel peripheral bypass graft that has now been launched in several European markets. The global market for TFT's products is estimated to be around 11 billion pounds. Cardiovascular diseases are the number one killer in the US and the UK. According to the American Heart Foundation over 60 million Americans have some form of cardiovascular disease. The graft market has seen little innovation in the past 20 years and the Company's proprietary SLF technology has the potential to extend both the quality and lifespan of cardiovascular devices.

Digital Supply Chain Transformation – Winning the AI/ML Way